ArticleF1000Research2025
Evaluation and Clinical Relevance of Plan Quality Indices in Intracavitary Brachytherapy for Cervical Cancer.
Article in F1000Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer remains to be a significant health concern globally, with India contributing to nearly one-quarter of cases worldwide. Intracavitary brachytherapy (ICBT) combined with external beam radiotherapy (EBRT) is the standard of care, optimizing tumour dose while sparing normal tissues. Plan quality indices such as Dose Homogeneity Index (DHI), Overdose Index (OI), Dose Non-uniformity Ratio (DNR), and Conformity Index (COIN) are crucial in evaluating treatment plans, yet their predictive clinical relevance remains underexplored. Methodology: In this Retrospective study, 84 patients with histologically confirmed cervical cancer undergoing definitive chemoradiation followed by CT-based HDR ICBT (Co-60) were evaluated. Plan indices were calculated per ICRU 89 and GEC-ESTRO guidelines. Correlation with tumour response (RECIST v1.1), toxicity (≥ grade 2 bladder/rectal), and clinical factors (FIGO stage, HRCTV volume, EQD2, BED, treatment duration) was assessed using t-tests, regression analyses, and Pearson's correlation. Results: Mean DHI was 0.403; OI 0.358; DNR 0.594; COIN 0.636. Higher DHI (p=0.019) and lower OI (p=0.004) were associated with tumour response; DNR and COIN were not significant. No plan index predicted ≥ grade 2 bladder or rectal toxicity. COIN correlated poorly with other indices. Multiple regression showed no consistent predictors of dosimetric indices. Logistic regression did not establish any index as a definitive predictor of 3-month response. Conclusion: Plan quality indices provide useful quantitative insights into dose distribution in High dose rate intracavitary brachytherapy for cervical cancer. In this study, DHI and OI showed an association with early tumour response, while no significant correlation was observed between plan indices and treatment-related toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.